Erasca, Inc. (ERAS) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 142 institutional investors hold a position in Erasca, Inc. (NASDAQ:ERAS).

• The collective stake of institutional investors in Erasca moved to 75.9% in September 2025, a shift down from the 77.1% reported for June 2025.
• The company experienced a 0.03% quarterly change in institutional shares held, alongside an increase of 8.40% in total owners annually.
• The latest 13F cycle for Erasca reveals that of 142 total investors, 58 funds grew their exposure, whereas 47 reduced theirs and 37 made no changes.
• Collectively, institutional investors increased their stake in Erasca to 215.18Mn shares as of September 2025, a change that is up by 63.55K shares quarter on quarter and down 15.51Mn shares year over year.
• The top institutional stake in Erasca as of September 30, 2025 belongs to Frazier Life Sciences Management, L.P., which owns 22.73Mn shares, or 8.01% of the company.
• Among the most significant buyers of Erasca during September 2025 were Vivo Capital, LLC (2.52Mn), Paradigm Biocapital Advisors LP (1.65Mn), GOLDMAN SACHS GROUP INC (697.34K), CITADEL ADVISORS LLC (341.40K), RENAISSANCE TECHNOLOGIES LLC (272.50K).
• Leading sellers of Erasca stock in September 2025 included MARSHALL WACE, LLP (1.55Mn), SILVERARC CAPITAL MANAGEMENT, LLC (1.20Mn), MILLENNIUM MANAGEMENT LLC (908.07K), Woodline Partners LP (540.00K), UBS Group AG (349.49K).
• The top 10 institutional holders of Erasca for the quarter ending September 2025 included Frazier Life Sciences Management, L.P. (22.73Mn), T. Rowe Price Investment Management, Inc. (20.23Mn), VR Adviser, LLC (17.86Mn), Logos Global Management LP (15.15Mn), BlackRock, Inc. (15.07Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (14.50Mn), Paradigm Biocapital Advisors LP (13.56Mn), VANGUARD GROUP INC (12.81Mn), ARCH Venture Management, LLC (11.06Mn), Vivo Capital, LLC (9.27Mn).